Imaging EGFR and HER2 by PET and SPECT: A Review

Medicinal Research Reviews

Volumn 34, Issue 3, 2014, Pages 596-643

  Corcoran, Emily B ^a   Hanson, Robert N ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

EGFR; HER2; PET; SPECT

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CETUXIMAB; CHIMERIC ANTIBODY 806; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUORINE 18; GALLIUM 67; GEFITINIB; IMMUNOGLOBULIN F(AB) FRAGMENT; IODINE 124; IODINE 125; IODINE 131; LAPATINIB; MONOCLONAL ANTIBODY; NANOBODY; PANITUMUMAB; PENTETATE INDIUM IN 111; PERTUZUMAB; TECHNETIUM 99M; TRACER; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST METASTASIS; CANCER PATIENT; DRUG TUMOR LEVEL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; NON INVASIVE PROCEDURE; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EGFR; HER2; PET; SPECT;

HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84897426237     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21299     Document Type: Article

References (146)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127-137.
2. Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009;62(4):314-324.
3. Emde A, Kostler WJ, Yarden Y. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2010;84(S1):E49-E67.
4. Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology 2004;45(3):207-217.
5. Laskin JJ, Sandler AB. Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treat Rev 2004;30(1):1-17.
6. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23(11):2445-2459.
7. Harris JL, Stocum M, Roberts L, Jiang CS, Lin J, Sprott K. Quest for the ideal cancer biomarker: An update on progress in capture and characterization of circulating tumor cells. Drug Dev Res 2013;74(2):138-147.
8. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199(4):418-423.
9. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Lee SH, Yoo NJ, Lee SH. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11(8):2879-2882.
10. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24(17):2666-2672.
11. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24(17):2659-2665.
12. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12(24):7261-7270.
13. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-1500.
14. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-13311.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-2139.
16. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004;64(24):8919-8923.
17. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba, II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97(5):339-346.
18. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005;6(5):279-286.
19. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97(8):1139-1145.
20. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25(22):3238-3245.
21. Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008;19(4):717-723.
22. Italiano A, Follana P, Caroli FX, Badetti JL, Benchimol D, Garnier G, Gugenheim J, Haudebourg J, Keslair F, Lesbats G, Lledo G, Roussel JF, Pedeutour F, Francois E. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008;15(2):649-654.
23. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-8654.
24. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13(7):1036-1043.
25. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D, Gugenheim J, Michiels JF. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: Biological and clinical implications. Ann Oncol 2005;16(9):1503-1507.
26. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22(23):4772-4778.
27. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93(5):552-556.
28. Rahmim A, Zaidi H. PET versus SPECT: Strengths, limitations and challenges. Nucl Med Commun 2008;29(3):193-207.
29. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [C-11]-labeled erlotinib: A micro-PET study on mice with lung tumor xenografts. Cancer Res 2009;69(3):873-878.
30. Zhang MR, Kumata K, Hatori A, Takai N, Toyohara J, Yamasaki T, Yanamoto K, Yui J, Kawamura K, Koike S, Ando K, Suzuki K. [11C]Gefitinib ([11c]Iressa): Radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma. Mol Imaging Biol 2010;12(2):181-191.
31. Holt DP, Ravert HT, Dannals RF, Pomper MG. Synthesis of [C-11]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Label Compd Radiopharm 2006;49(10):883-888.
32. Wang JQ, Gao MZ, Miller KD, Sledge GW, Zheng QH. Synthesis of [C-11]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 2006;16(15):4102-4106.
33. DeJesus O, Murali D, Flores L, Converse A, Dick DW, Oakes TR, Roberts A, Nickles R. Synthesis of [F-18]-ZD1839 as a PET imaging agent for epidermal growth factor receptors. J Label Compd Radiopharm 2003;46:S1.
34. Seimbille YP, Michael E, Czernin J, Silverman DHS. Fluorine-18 labeling of 6, 7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of 18F-Iressa and related molecular probes. J Label Compd Radiopharm 2005;48:829-843.
35. Lappchen T, Vlaming ML, Custers E, Lub J, Sio CF, DeGroot J, Steinbach OC. Automated synthesis of [18F]gefitinib on a modular system. Appl Radiat Isotopes 2012;70(1):205-209.
36. Murali D, Flores L, Converse A, Bartlett R, Barnhart T, Armstrong E, Nickles R, Harari P, DeJesus O. Evaluation of [F-18]Iressa as a PET imaging agent for tumors overexpressing epidermal growth factor (EGF) receptors. J Label Compd Radiopharm 2005;44:S294.
37. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008;35(6):1089-1099.
38. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NMT, Chisin R, Gazit A, Levitzki A, Mishani E. Potential F-18-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 2001;28(4):359-374.
39. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, Nexo E, Meldgaard P. Erlotinib accumulation in brain metastases from non-small cell lung cancer: Visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011;6(7):1287-1289.
40. Fredriksson A, Johnstrom P, Thorell JO, von Heijne G, Hassan M, Eksborg S, Kogner P, Borgstrom P, Ingvar M, Stone-Elander S. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999;65(2):165-174.
41. Wang H, Yu J, Yang G, Song X, Sun X, Zhao S, Mu D. Assessment of 11C-labeled-4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci 2007;98(9):1413-1416.
42. Meng X, Loo BW, Ma L, Murphy JD, Sun XD, Yu JM. Molecular imaging with C-11-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: A pilot study. J Nucl Med 2011;52(10):1573-1579.
43. Hirata M, Kanai Y, Naka S, Matsumuro K, Kagawa S, Yoshimoto M, Ohmomo Y. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT. Ann Nucl Med 2011;25(2):117-124.
44. Mulholland GK, Zheng QH, Winkle WL, Carlson KA. Synthesis and biodistribution of new C-11 and F-18 labeled epidermal growth factor receptor ligands. J Nucl Med 1997;38(5):529-529.
45. Fernandes C, Oliveira C, Gano L, Bourkoula A, Pirmettis I, Santos I. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer. Bioorg Med Chem 2007;15(12):3974-3980.
46. Neto C, Fernandes C, Oliveira MC, Gano L, Mendes F, Kniess T, Santos I. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents. Nucl Med Biol 2012;39(2):247-260.
47. Fernandes C, Santos IC, Santos I, Pietzsch HJ, Kunstler JU, Kraus W, Rey A, Margaritis N, Bourkoula A, Chiotellis A, Paravatou-Pestsotas M, Pirmettis I. Rhenium and technetium complexes bearing quinazoline derivatives: Progress towards a (99m)Tc biomarker for EGFR-TK imaging. Dalton Trans 2008;37(24):3215-3225.
48. Bourkoula A, Paravatou-Petsotas M, Papadopoulos A, Santos I, Pietzsch HJ, Livaniou E, Pelecanou M, Papadopoulos M, Pirmettis I. Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging. Eur J Med Chem 2009;44(10):4021-4027.
49. Garcia R, Fouskova P, Gano L, Paulo A, Campello P, Toth E, Santos I. A quinazoline-derivative DOTA-type gallium(III) complex for targeting epidermal growth factor receptors: Synthesis, characterisation and biological studies. J Biol Inorg Chem 2009;14(2):261-271.
50. Garcia R, Kubicek V, Drahos B, Gano L, Santos IC, Campello P, Paulo A, Toth E, Santos I. Synthesis, characterization and biological evaluation of In(III) complexes anchored by DOTA-like chelators bearing a quinazoline moiety. Metallomics 2010;2(8):571-580.
51. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001;44(17):2719-2734.
52. Ortu G, Ben-David I, Rozen Y, Freedman NMT, Chisin R, Levitzki A, Mishani E. Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer 2002;101(4):360-370.
53. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Ben David I, Levitzki A, Shaul M. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 2004;31(4):469-476.
54. Dissoki S, Laky D, Mishani E. Fluorine-18 labeling of ML04-Presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. J Label Compd Radiopharm 2006;49(6):533-543.
55. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D, Levitzki A, Mishani E. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 2007;34(1):55-70.
56. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, Mishani E. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 2004;12(13):3421-3429.
57. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, Shaul M, Levitzki A. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 2005;48(16):5337-5348.
58. Pal A, Glekas A, Doubrovin M, Balatoni J, Narnavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG. Molecular imaging of EGFR kinase activity in tumors with I-124-labeled small molecular tracer and positron emission tomography (vol 8, pg 262, 2006). Mol Imaging Biol 2006;8(6):373-373.
59. Kobus D, Giesen Y, Ullrich R, Backes H, Neumaier B. A fully automated two-step synthesis of an F-18-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors. Appl Radiat Isotopes 2009;67(11):1977-1984.
60. Dissoki S, Aviv Y, Laky D, Abourbeh G, Levitzki A, Mishani E. The effect of the [F-18]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety-An EGFR putative irreversible inhibitor. Appl Radiat Isotopes 2007;65(10):1140-1151.
61. Pal A, Balatoni JA, Mukhopadhyay U, Ogawa K, Gonzalez-Lepera C, Shavrin A, Volgin A, Tong W, Alauddin MM, Gelovani JG. Radiosynthesis and initial in vitro evaluation of [F-18]F-PEG(6)-IPQA-A novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas. Mol Imaging Biol 2011;13(5):853-861.
62. Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L, Young D, Volgin AY, Najjar AM, Krasnykh V, Tong W, Alauddin MM, Gelovani JG. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci USA 2011;108(4):1603-1608.
63. Pantaleo MA, Mishani E, Nanni C, Landuzzi L, Boschi S, Nicoletti G, Dissoki S, Paterini P, Piccaluga PP, Lodi F, Lollini PL, Fanti S, Biasco G. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol 2010;12(6):616-625.
64. Capala J, Barth RF, Bailey MQ, Fenstermaker RA, Marek MJ, Rhodes BA. Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats. Bioconjugate Chem 1997;8(3):289-295.
65. Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, Carlsson J, Bergstrom M, Langstrom B, Tolmachev V. Preparation and evaluation of Ga-68-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005;46(11):1881-1888.
66. Li WH, Niu G, Lang LX, Guo N, Ma Y, Kiesewetter DO, Backer JM, Shen BZ, Chen XY. PET imaging of EGF receptors using [F-18]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging 2012;39(2):300-308.
67. Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004;143(1):99-106.
68. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009;36(1):81-93.
69. Bejot R, Goggi J, Moonshi SS, Padmanabhan P, Bhakoo KK. Aminooxy-functionalized DOTA for radiolabeling of oxidized antibodies: Evaluation of site-specific In-111-labeled trastuzumab. J Label Compd Radiopharm 2012;55(9):346-353.
70. Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One 2010;5(1):e8859.
71. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009;50(6):974-981.
72. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87(5):586-592.
73. Zeglis BM, Mohindra P, Weissmann GI, Divilov V, Hilderbrand SA, Weissleder R, Lewis JS. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjugate Chem 2011;22(10):2048-2059.
74. Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG, Schroder CP. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Oncol 2012;30(6):e74-e75.
75. Munnink THO, de Korte MA, Nagengast WB, Timmer-Bosscha H, Schroder CP, de Jong JR, van Dongen GAMS, Jensen MR, Quadt C, Lub-de Hooge MN, de Vries EGE. Zr-89-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010;46(3):678-684.
76. Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Watanabe S, Ishioka NS, Endo K. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET. Cancer Sci 2010;101(4):1045-1050.
77. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008;49(9):1472-1479.
78. Cai WB, Chen K, Mohamedali KA, Cao QZ, Gambhir SS, Rosenblum MG, Chen XY. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006;47(12):2048-2056.
79. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 2002;62(19):5485-5488.
80. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2(2):127-137.
81. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer cell 2004;5(4):317-328.
82. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421(6924):756-760.
83. McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009;50(8):1340-1348.
84. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34(6):850-858.
85. Sadri K, Ren Q, Zhang K, Paudyal B, Devadhas D, Rodeck U, Thakur M. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma. Nucl Med Commun 2011;32(7):563-569.
86. Huhtala T, Laakkonen P, Sallinen H, Yla-Herttuala S, Narvanen A. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies. Nucl Med Biol 2010;37(8):957-964.
87. Achmad A, Hanaoka H, Yoshioka H, Yamamoto S, Tominaga H, Araki T, Ohshima Y, Oriuchi N, Endo K. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci 2012;103(3):600-605.
88. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50(1):123-131.
89. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010;37(7):1368-1376.
90. Mano M, Humblet Y. Drug insight: Panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 2008;5(7):415-425.
91. Wu M, Rivkin A, Pham T. Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 2008;30(1):14-30.
92. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: Panitumumab (Vectibix). Oncologist 2007;12(5):577-583.
93. Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, Milenic DE. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol 2009;157(8):1541-1548.
94. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med 2010;51(6):942-950.
95. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 2012;53(1):113-120.
96. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009;50(7):1116-1123.
97. Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 2005;92(6):1069-1077.
98. Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F, Ritter G, Jungbluth AA, Old LJ, Ward CW, Burgess AW, Wittrup KD, Scott AM. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004;279(29):30375-30384.
99. Walker F, Orchard SG, Jorissen RN, Hall NE, Zhang HH, Hoyne PA, Adams TE, Johns TG, Ward C, Garrett TP, Zhu HJ, Nerrie M, Scott AM, Nice EC, Burgess AW. CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. J Biol Chem 2004;279(21):22387-22398.
100. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 2003;100(2):639-644.
101. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007;104(10):4071-4076.
102. Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J Nucl Med 2010;51(6):967-972.
103. Chan C, Scollard DA, McLarty K, Smith S, Reilly RM. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res 2011;1(1):15.
104. Razumienko EJ, Scollard DA, Reilly RM. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J Nucl Med 2012;53(12):1943-1950.
105. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77(9):1405-1412.
106. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res 2011;17(6):1509-1520.
107. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 2007;7(4):555-568.
108. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S, Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005;20(3):239-248.
109. Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjoberg S, Tolmachev V. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem 2005;16(6):1547-1555.
110. Orlova A, Nilsson FY, Wikman M, Widstrom C, Stahl S, Carlsson J, Tolmachev V. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006;47(3):512-519.
111. Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006;47(5):846-853.
112. Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: Direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009;50(3):417-425.
113. Tran T, Engfeldt T, Orlova A, Sandstrom M, Feldwisch J, Abrahmsen L, Wennborg A, Tolmachev V, Karlstrom AE. (99m)Tc-maEEE-Z(HER2:342), an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjugate Chem 2007;18(6):1956-1964.
114. Tran TA, Ekblad T, Orlova A, Sandstrom M, Feldwisch J, Wennborg A, Abrahmsen L, Tolmachev V, Eriksson Karlstrom A. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 affibody molecules. Bioconjugate Chem 2008;19(12):2568-2576.
115. Engfeldt T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L, Wennborg A, Karlstrom AE, Tolmachev V. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific affibody molecule. Eur J Nucl Med Mol Imaging 2007;34(11):1843-1853.
116. Engfeldt T, Orlova A, Tran T, Bruskin A, Widstrom C, Karlstrom AE, Tolmachev V. Imaging of HER2-expressing tumours using a synthetic affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007;34(5):722-733.
117. Ekblad T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L, Wennborg A, Karlstrom AE, Tolmachev V. Development and preclinical characterisation of 99mTc-labelled affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008;35(12):2245-2255.
118. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2:342)-affibody molecule-A new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35(5):1008-1018.
119. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009;50(7):1131-1139.
120. Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med 2012;53(4):629-637.
121. Hoppmann S, Miao Z, Liu S, Liu H, Ren G, Bao A, Cheng Z. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjugate Chem 2011;22(3):413-421.
122. Tolmachev V, Velikyan I, Sandstrom M, Orlova A. A HER2-binding affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010;37(7):1356-1367.
123. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001;345(13):995-996.
124. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24(15):2276-2282.
125. de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WT, Sluiter WJ, van Veldhuisen DJ, Suter TM, Sleijfer DT, Perik PJ. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007;43(14):2046-2051.
126. Webster JM, Zhang R, Gambhir SS, Cheng Z, Syud FA. Engineered two-helix small proteins for molecular recognition. Chembiochem 2009;10(8):1293-1296.
127. Ren G, Webster JM, Liu Z, Zhang R, Miao Z, Liu H, Gambhir SS, Syud FA, Cheng Z. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. Amino Acids 2012;43(1):405-413.
128. Ren G, Zhang R, Liu Z, Webster JM, Miao Z, Gambhir SS, Syud FA, Cheng Z. A 2-helix small protein labeled with Ga-68 for PET imaging of HER2 expression. J Nucl Med 2009;50(9):1492-1499.
129. Miao Z, Ren G, Jiang L, Liu H, Webster JM, Zhang R, Namavari M, Gambhir SS, Syud F, Cheng Z. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging 2011;38(11):1977-1984.
130. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, Zhang R, Lee B, Syud FA, Gambhir SS. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008;49(5):804-813.
131. Cheng Z, De Jesus OP, Kramer DJ, De A, Webster JM, Gheysens O, Levi J, Namavari M, Wang S, Park JM, Zhang R, Liu H, Lee B, Syud FA, Gambhir SS. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2010;12(3):316-324.
132. Heskamp S, Laverman P, Rosik D, Boschetti F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V, Boerman OC. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med 2012;53(1):146-153.
133. Tolmachev V, Rosik D, Wallberg H, Sjoberg A, Sandstrom M, Hansson M, Wennborg A, Orlova A. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 affibody molecule: Aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37(3):613-622.
134. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, Hodik M, Stahl S, Frejd FY, Orlova A. Affibody molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry. J Nucl Med 2009;50(2):274-283.
135. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjugate Chem 2010;21(5):947-954.
136. Miao Z, Ren G, Liu H, Qi S, Wu S, Cheng Z. PET of EGFR expression with an 18F-labeled affibody molecule. J Nucl Med 2012;53(7):1110-1118.
137. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, Rothbauer U, Stijlemans B, Tillib S, Wernery U, Wyns L, Hassanzadeh-Ghassabeh G, Saerens D. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 2009;128(1-3):178-183.
138. Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008;49(5):788-795.
139. Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, Muyldermans S, Bossuyt A, Lahoutte T. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011;6(2):85-92.
140. Vosjan MJWD, Perk LR, Roovers RC, Visser GWM, Stigter-van Walsum M, Henegouwen PMPVE, van Dongen GAMS. Facile labelling of an anti-epidermal growth factor receptor nanobody with Ga-68 via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 2011;38(4):753-763.
141. Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10(3):167-175.
142. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011;25(7):2433-2446.
143. Pantaleo MA, Nannini M, Fanti S, Boschi S, Lollini PL, Biasco G. Molecular imaging of EGFR: It's time to go beyond receptor expression. J Nucl Med 2009;50(7):1195-1196; author reply 1196, 1197.
144. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WEE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13(1):33-42.
145. Mauro LV, Dalurzo M, Carlini MJ, Smith D, Nunez M, Simian M, Lastiri J, Vasallo B, Bal de Kier Joffe E, Pallotta MG, Puricelli L. Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer. Oncol Rep 2010;24(5):1331-1338.
146. Cronin J, McAdam E, Danikas A, Tselepis C, Griffiths P, Baxter J, Thomas L, Manson J, Jenkins G. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol 2011;106(1):46-56.